ArticleJournal for immunotherapy of cancer2024

First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments.

Aung Naing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.